From the Basil I. Hirschowitz Center of Endoscopic Excellence, Division of Gastroenterology and Hepatology, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama.
Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama.
ASAIO J. 2018 Jul/Aug;64(4):472-479. doi: 10.1097/MAT.0000000000000766.
Gastrointestinal bleeding (GIB) is common in patients with continuous-flow left ventricular assist devices (CF-LVADs) possibly because of changes in blood flow. We aimed to test the hypothesis that a low pulsatility index (PI) is associated with an increased hazard of overt GIB in patients with CF-LVADs. We conducted a retrospective cohort study of patients who had a HeartMate II (HMII) CF-LVAD implanted at our center. The study end-point was the first overt GIB causing or occurring during a hospitalization between 6 days and 6 months after HMII implantation. HMII PI was recorded at 48 hours and at 1, 3, and 6 month intervals after implantation. We analyzed the associations of PI and clinical variables with the hazard of overt GIB. Ninety-five patients met eligibility criteria. PI ranged from 2.5 to 5.9 (low PI < 4.15 and high PI ≥ 4.15 on the basis of receiver operating characteristic curve analysis). Seventeen (18%) patients experienced overt GIB. In a multivariable model, only lower baseline hemoglobin was a significant predictor of an increased hazard of overt GIB. After adjusting for the baseline hemoglobin, low PI was independently associated with an increased hazard of overt GIB in our cohort of HMII recipients.
胃肠道出血(GIB)在持续血流左心室辅助装置(CF-LVAD)患者中很常见,可能是由于血流变化所致。我们旨在检验假设,即低搏动指数(PI)与 CF-LVAD 患者显性 GIB 的发生风险增加相关。我们对在我们中心植入 HeartMate II(HMII)CF-LVAD 的患者进行了回顾性队列研究。研究终点是在 HMII 植入后 6 天至 6 个月期间因或发生在住院期间的首次显性 GIB。HMII PI 在植入后 48 小时以及 1、3 和 6 个月时记录。我们分析了 PI 和临床变量与显性 GIB 发生风险的关联。95 名患者符合入选标准。PI 范围为 2.5 至 5.9(根据接收者操作特征曲线分析,低 PI < 4.15,高 PI ≥ 4.15)。17 名(18%)患者发生显性 GIB。在多变量模型中,只有较低的基线血红蛋白是显性 GIB 发生风险增加的显著预测因子。在调整基线血红蛋白后,低 PI 与我们的 HMII 受者队列中显性 GIB 的发生风险增加独立相关。